| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Human fibroblasts and human cancer cells proliferate at IMS2186 (0.3-10 μM; 22 h); their corresponding IC50 values are 1.0-3.0 μM and 0.3-3.0 μM[1]. With an IC50 of 0.1-0.3 μM, IMS2186 (0-10 μM; 22 h) suppresses the production of the pro-inflammatory cytokine PGE2/TNF-a in macrophages [1]. With an IC50 of 1 μM, IMS2186 (0.1-10 μM; 1.5 h) similarly prevents macrophage migration [1].
|
|---|---|
| ln Vivo |
No ocular toxicity was seen following delivery of IMS2186 (2.5 mg in 0.5 mL; intravitreal injection; single dose) to the eye [1]. IMS2186 (100 μg/eye, i.e. 2.0 μL of 50 μg/μL solution; single dosage) displays anti-aging effects in a vascular model of laser-induced choroidal neovascularization (CNV) [1].
|
| Cell Assay |
Cell cycle analysis[1]
Cell Types: Cancer H460 cells Tested Concentrations: 3 μM 0.3-1 μM[1]. , 10 μM Incubation Duration: Experimental Results: Demonstrates anti-proliferative activity mediated by arresting the cell cycle at G2/M. |
| Animal Protocol |
Animal/Disease Models: Laser-induced CNV rat model [1]
Doses: 100 μg/eye, 50 μg/eye solution 2.0 μL μL Route of Administration: intravitreal injection; single dose Experimental Results: in lesion area measurement, compared with PBS The area has been diminished by 30%. |
| References |
[1]. Falkenstein IA, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res. 2008 Jul;33(7):599-609.
|
| Molecular Formula |
C18H16O4
|
|---|---|
| Molecular Weight |
296.317245483398
|
| Exact Mass |
296.105
|
| CAS # |
1031206-36-6
|
| PubChem CID |
24987039
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.367
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
444
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC2=C(C=C1)OCC(=CC3=CC(=C(C=C3)OC)O)C2=O
|
| InChi Key |
BZCADTHMZLYKAR-MDWZMJQESA-N
|
| InChi Code |
InChI=1S/C18H16O4/c1-11-3-5-16-14(7-11)18(20)13(10-22-16)8-12-4-6-17(21-2)15(19)9-12/h3-9,19H,10H2,1-2H3/b13-8+
|
| Chemical Name |
(3E)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]-6-methylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~66.67 mg/mL (~224.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (4.22 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3747 mL | 16.8737 mL | 33.7473 mL | |
| 5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | |
| 10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
